{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:28:35Z","timestamp":1773106115858,"version":"3.50.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1097\/aco.0000000000000210","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T08:51:10Z","timestamp":1434617470000},"page":"411-416","source":"Crossref","is-referenced-by-count":19,"title":["Emerging therapies for the treatment of sepsis"],"prefix":"10.1097","volume":"28","author":[{"given":"Jean-Louis","family":"Vincent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210129","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1097\/CCM.0b013e3181f208ac","article-title":"We should abandon randomized controlled trials in the intensive care unit.","volume":"38","author":"Vincent","year":"2010","journal-title":"Crit Care Med"},{"key":"R2-5-20210129","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0140-6736(12)61815-7","article-title":"Sepsis definitions: time for change.","volume":"381","author":"Vincent","year":"2013","journal-title":"Lancet"},{"key":"R3-5-20210129","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCPSCCM Consensus Conference Committee. American College of Chest PhysiciansSociety of Critical Care Medicine.","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"R4-5-20210129","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jama.2014.2637","article-title":"Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.","volume":"311","author":"Kaukonen","year":"2014","journal-title":"JAMA"},{"key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu750","article-title":"Comparison of trends in sepsis incidence and coding using administrative claims versus objective clinical data.","volume":"60","author":"Rhee","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","article-title":"Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.","volume":"309","author":"Opal","year":"2013","journal-title":"JAMA"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/CCM.0000000000000043","article-title":"Evaluating the efficacy and safety of two doses of the polyclonal antitumor necrosis factor-alpha fragment antibody AZD9773 in adult patients with severe sepsis andor septic shock: randomized, double-blind, placebo-controlled phase IIb study.","volume":"42","author":"Bernard","year":"2014","journal-title":"Crit Care Med"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"e2010024","DOI":"10.4084\/mjhid.2010.024","article-title":"Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.","volume":"2","author":"Semeraro","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R10-5-20210129","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.39398.682500.25","article-title":"Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis.","volume":"335","author":"Afshari","year":"2007","journal-title":"BMJ"},{"key":"R11-5-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"R12-5-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis.","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-5-20210129","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock.","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1473-3099(12)70157-3","article-title":"Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.","volume":"12","author":"Kalil","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R15-5-20210129","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway.","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1172\/JCI22782","article-title":"The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.","volume":"115","author":"Abeyama","year":"2005","journal-title":"J Clin Invest"},{"key":"R17-5-20210129","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/CCM.0b013e31828e9b03","article-title":"A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.","volume":"41","author":"Vincent","year":"2013","journal-title":"Crit Care Med"},{"key":"R18-5-20210129","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/cc10597","article-title":"Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.","volume":"16","author":"Shankar-Hari","year":"2012","journal-title":"Crit Care"},{"key":"R19-5-20210129","first-page":"2686","article-title":"Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis.","volume":"35","author":"Laupland","year":"2007","journal-title":"Crit Care Med"},{"key":"R20-5-20210129","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1186\/s13054-015-0793-0","article-title":"The original sins of clinical trials with intravenous immunoglobulins in sepsis.","volume":"19","author":"Almansa","year":"2015","journal-title":"Crit Care"},{"key":"R21-5-20210129","first-page":"2677","article-title":"Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock.","volume":"35","author":"Kreymann","year":"2007","journal-title":"Crit Care Med"},{"key":"R22-5-20210129","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1007\/s00134-014-3474-6","article-title":"Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock.","volume":"40","author":"Cavazzuti","year":"2014","journal-title":"Intensive Care Med"},{"key":"R23-5-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/SHK.0b013e3181a2c0b2","article-title":"Gamma-globulin levels in patients with community-acquired septic shock.","volume":"32","author":"Taccone","year":"2009","journal-title":"Shock"},{"key":"R24-5-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012.","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"R25-5-20210129","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/PCC.0000000000000193","article-title":"A single nucleotide polymorphism in the corticotropin receptor gene is associated with a blunted cortisol response during pediatric critical illness.","volume":"15","author":"Jardine","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"R26-5-20210129","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1164\/rccm.201410-1864OC","article-title":"Developing a clinically feasible personalized medicine approach to pediatric septic shock.","volume":"191","author":"Wong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-5-20210129","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1214969","article-title":"Reduced cortisol metabolism during critical illness.","volume":"368","author":"Boonen","year":"2013","journal-title":"N Engl J Med"},{"key":"R28-5-20210129","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1097\/01.CCM.0000063046.82359.4A","article-title":"Circulating vasopressin levels in septic shock.","volume":"31","author":"Sharshar","year":"2003","journal-title":"Crit Care Med"},{"key":"R29-5-20210129","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1097\/01.CCM.0000186749.34028.40","article-title":"Arginine vasopressin in 316 patients with advanced vasodilatory shock.","volume":"33","author":"Luckner","year":"2005","journal-title":"Crit Care Med"},{"key":"R30-5-20210129","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/01.CIR.0000066692.71008.BB","article-title":"Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study.","volume":"107","author":"Dunser","year":"2003","journal-title":"Circulation"},{"key":"R31-5-20210129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"R32-5-20210129","doi-asserted-by":"crossref","first-page":"R979","DOI":"10.1152\/ajpregu.00520.2001","article-title":"Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats.","volume":"282","author":"Bucher","year":"2002","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R33-5-20210129","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1097\/CCM.0b013e318180b51d","article-title":"Role of nuclear factor-kappaB-dependent induction of cytokines in the regulation of vasopressin V1A-receptors during cecal ligation and puncture-induced circulatory failure.","volume":"36","author":"Schmidt","year":"2008","journal-title":"Crit Care Med"},{"key":"R34-5-20210129","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1097\/CCM.0000000000000300","article-title":"The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis.","volume":"42","author":"Maybauer","year":"2014","journal-title":"Crit Care Med"},{"key":"R35-5-20210129","first-page":"319","article-title":"A physiologic function for alkaline phosphatase: endotoxin detoxification.","volume":"76","author":"Poelstra","year":"1997","journal-title":"Lab Invest"},{"key":"R36-5-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2613.2003.00345.x","article-title":"Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide.","volume":"84","author":"Kapojos","year":"2003","journal-title":"Int J Exp Pathol"},{"key":"R37-5-20210129","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/01.CCM.0000229887.70579.29","article-title":"Beneficial effects of alkaline phosphatase in septic shock.","volume":"34","author":"Su","year":"2006","journal-title":"Crit Care Med"},{"key":"R38-5-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CCM.0b013e31819598af","article-title":"Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.","volume":"37","author":"Heemskerk","year":"2009","journal-title":"Crit Care Med"},{"key":"R39-5-20210129","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/cc11159","article-title":"Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.","volume":"16","author":"Pickkers","year":"2012","journal-title":"Crit Care"},{"key":"R40-5-20210129","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1038\/srep04220","article-title":"Interferon beta protects against lethal endotoxic and septic shock through SIRT1 upregulation.","volume":"4","author":"Yoo","year":"2014","journal-title":"Sci Rep"},{"key":"R41-5-20210129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S2213-2600(13)70259-5","article-title":"The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.","volume":"2","author":"Bellingan","year":"2014","journal-title":"Lancet Respir Med"},{"key":"R42-5-20210129","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/CCM.0b013e3181962316","article-title":"Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial.","volume":"37","author":"Payen","year":"2009","journal-title":"Crit Care Med"},{"key":"R43-5-20210129","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa0902413","article-title":"Intensity of continuous renal-replacement therapy in critically ill patients.","volume":"361","author":"Bellomo","year":"2009","journal-title":"N Engl J Med"},{"key":"R44-5-20210129","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/jama.2009.856","article-title":"Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.","volume":"301","author":"Cruz","year":"2009","journal-title":"JAMA"},{"key":"R45-5-20210129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrneph.2009.146","article-title":"Sepsis: clearing the blood in sepsis.","volume":"5","author":"Vincent","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"R46-5-20210129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/1745-6215-15-218","article-title":"The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.","volume":"15","author":"Klein","year":"2014","journal-title":"Trials"},{"key":"R47-5-20210129","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R48-5-20210129","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1164\/rccm.201301-0036CP","article-title":"Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation.","volume":"187","author":"Leentjens","year":"2013","journal-title":"Time for a paradigm change Am J Respir Crit Care Med"},{"key":"R49-5-20210129","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc10031","article-title":"Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.","volume":"15","author":"Bo","year":"2011","journal-title":"Crit Care"},{"key":"R50-5-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.molmed.2014.01.002","article-title":"The new normal: immunomodulatory agents against sepsis immune suppression.","volume":"20","author":"Hutchins","year":"2014","journal-title":"Trends Mol Med"},{"key":"R51-5-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s13054-015-0737-8","article-title":"Metabolic and nutritional support of critically ill patients: consensus and controversies.","volume":"19","author":"Preiser","year":"2015","journal-title":"Crit Care"},{"key":"R52-5-20210129","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/CCM.0b013e31828a24c6","article-title":"The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials.","volume":"41","author":"Alhazzani","year":"2013","journal-title":"Crit Care Med"},{"key":"R53-5-20210129","first-page":"222","article-title":"Clinical review: fever in septic ICU patients - friend or foe Crit C","volume":"15","author":"Launey","year":"2011","journal-title":"are"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000000210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:44:13Z","timestamp":1620931453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001503-201508000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000000210","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725570146.793526341","asserted-by":"object"}]},"ISSN":["0952-7907"],"issn-type":[{"value":"0952-7907","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}